
Commercialization of our second SARS-CoV-2 detection test by RT-qPCR
NewsLaboratoire OBO, France – 21 March 2022
A new CE-IVD marked test, the OSANTYS SARS-CoV-2 Duo RT-qPCR kit, allows for rapid (without extraction) and standardised detection of Sars-Cov-2 from a simple cell lysate, regardless of the type of…


New HPV test soon on the market
News Laboratoire OBO, France – 04 February 2022
The ongoing development of a high-risk human papillomavirus (HPV) detection test using real-time PCR with partial genotyping. This kit will allow for the individualised identification of 3 genotypes…


Our products for the detection of Sars-CoV-2 present at RICAI 2021
NewsLaboratoire OBO, France – 06 December 2021
Laboratoire OBO is attending the RICAI conference to present its 1st marketed test in the fight against the Covid-19. We will be represented by the company R-Biopharm, who can tell you all about…



Commercialization of our first SARS-CoV-2 detection test by RT-qPCR
News Laboratoire OBO, France – 28 June 2021
1st CE-IVD marked SARS-CoV-2 detection test for Laboratoire OBO following its validation by the CNR.
In its commitment to fight the COVID-19 pandemic, Laboratoire OBO was able to produce its first…


CNR validation of our first SARS-CoV-2 detection test by RT-qPCR
News Laboratoire OBO, France – 17 June 2021
The CNR has validated the 1st RT-qPCR test that can detect SARS-CoV-2 launched under the OSANTYS brand, a trademark of Laboratoire OBO. The evaluation of the analytical performance for detecting SARS-CoV-2…